Skip to content
10-Q

Quarterly Report

VitaNova Life Sciences Corporation VNOV

0001683168-26-001858

← back to feed
Filed
Mar 16, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2026 · Mar 11, 2026 8.34M sh
Shares Diluted Q3 2026 · Jan 31, 2026 8.34M sh
Shares Diluted Q3 2026 · Jan 31, 2026 8.34M sh
Shares Diluted restated Q3 2026 · Jan 31, 2025 8.34M sh
Shares Diluted restated Q3 2026 · Jan 31, 2025 8.34M sh
Operating Cash Flow Q3 2026 · Jan 31, 2026 $386.09K
Operating Cash Flow Q3 2026 · Jan 31, 2025 −$286.36K
Stockholders Equity Q3 2026 · Jan 31, 2026 $1.85M
Stockholders Equity Q3 2026 · Oct 31, 2025 $1.9M
Stockholders Equity Q3 2026 · Jul 31, 2025 $1.86M
Stockholders Equity Q3 2026 · Apr 30, 2025 $1.91M
Stockholders Equity Q3 2026 · Jan 31, 2025 $1.11M
Stockholders Equity Q3 2026 · Oct 31, 2024 $1.03M
Stockholders Equity Q3 2026 · Jul 31, 2024 $1M
Stockholders Equity Q3 2026 · Apr 30, 2024 $1.06M
Current Liabilities Q3 2026 · Jan 31, 2026 $457.98K
Current Liabilities Q3 2026 · Apr 30, 2025 $347.57K
Total Liabilities Q3 2026 · Jan 31, 2026 $457.98K
Total Liabilities Q3 2026 · Apr 30, 2025 $347.57K
Current Assets Q3 2026 · Jan 31, 2026 $2.31M
Current Assets Q3 2026 · Apr 30, 2025 $2.26M
Total Assets Q3 2026 · Jan 31, 2026 $2.31M
Total Assets Q3 2026 · Apr 30, 2025 $2.26M
Eps Diluted Q3 2026 · Jan 31, 2026 −$0.01
Eps Diluted Q3 2026 · Jan 31, 2026 −$0.01
Eps Diluted restated Q3 2026 · Jan 31, 2025 $0.01
Eps Diluted restated Q3 2026 · Jan 31, 2025 $0.01
Eps Basic Q3 2026 · Jan 31, 2026 −$0.01
Eps Basic Q3 2026 · Jan 31, 2026 −$0.01
Eps Basic restated Q3 2026 · Jan 31, 2025 $0.01
Eps Basic restated Q3 2026 · Jan 31, 2025 $0.01
Sga Expense Q3 2026 · Jan 31, 2026 $219.6K
Sga Expense Q3 2026 · Jan 31, 2026 $405.34K
Sga Expense Q3 2026 · Jan 31, 2025 $30.67K
Sga Expense Q3 2026 · Jan 31, 2025 $128.35K
Net Income Q3 2026 · Jan 31, 2026 −$44.36K
Net Income Q3 2026 · Jan 31, 2026 −$54.85K
Net Income Q3 2026 · Oct 31, 2025 $35.81K
Net Income Q3 2026 · Jul 31, 2025 −$46.3K
Net Income Q3 2026 · Jan 31, 2025 $72.98K
Net Income Q3 2026 · Jan 31, 2025 $50.41K
Net Income Q3 2026 · Oct 31, 2024 $32.65K
Net Income Q3 2026 · Jul 31, 2024 −$55.21K
Operating Income Q3 2026 · Jan 31, 2026 $46.73K
Operating Income Q3 2026 · Jan 31, 2026 $113.46K
Operating Income Q3 2026 · Jan 31, 2025 $108.87K
Operating Income Q3 2026 · Jan 31, 2025 $126.06K
Gross Profit Q3 2026 · Jan 31, 2026 $316.34K
Gross Profit Q3 2026 · Jan 31, 2026 $645.93K
Gross Profit Q3 2026 · Jan 31, 2025 $189.31K
Gross Profit Q3 2026 · Jan 31, 2025 $418.32K
Cost Of Revenue Q3 2026 · Jan 31, 2026 $393.28K
Cost Of Revenue Q3 2026 · Jan 31, 2026 $594.71K
Cost Of Revenue Q3 2026 · Jan 31, 2025 $119.01K
Cost Of Revenue Q3 2026 · Jan 31, 2025 $290.59K
Revenue Q3 2026 · Jan 31, 2026 $709.63K
Revenue Q3 2026 · Jan 31, 2026 $1.24M
Revenue Q3 2026 · Jan 31, 2025 $308.32K
Revenue Q3 2026 · Jan 31, 2025 $708.91K